Vir Biotechnology Files 8-K on Material Agreement & Financials

Ticker: VIR · Form: 8-K · Filed: 2024-02-22T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, financial-condition, 8-K

TL;DR

**Vir Bio just dropped an 8-K about a new material agreement and financials, keep an eye out for details!**

AI Summary

Vir Biotechnology, Inc. filed an 8-K on February 22, 2024, reporting an event that occurred on February 21, 2024. The filing indicates an entry into a material definitive agreement and provides information on results of operations and financial condition, along with financial statements and exhibits. The company, based in San Francisco, CA, operates in the biological products industry.

Why It Matters

This filing signals a significant business development for Vir Biotechnology, potentially impacting its future operations and financial performance, which investors will closely monitor.

Risk Assessment

Risk Level: medium — The filing mentions a 'material definitive agreement' without specifics, which could introduce unknown risks or opportunities.

Key Players & Entities

FAQ

What was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on February 21, 2024.

What is the name of the registrant company?

The registrant company is Vir Biotechnology, Inc.

What items of information were included in this 8-K filing?

The 8-K filing included information on 'Entry into a Material Definitive Agreement', 'Results of Operations and Financial Condition', and 'Financial Statements and Exhibits'.

Where are Vir Biotechnology, Inc.'s principal executive offices located?

Vir Biotechnology, Inc.'s principal executive offices are located at 1800 Owens Street, Suite 900, San Francisco, California 94158.

What is the Commission File Number for Vir Biotechnology, Inc.?

The Commission File Number for Vir Biotechnology, Inc. is 001-39083.

From the Filing

0001628280-24-006346.txt : 20240222 0001628280-24-006346.hdr.sgml : 20240222 20240222161249 ACCESSION NUMBER: 0001628280-24-006346 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240221 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240222 DATE AS OF CHANGE: 20240222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 24664869 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 vir-20240221.htm 8-K vir-20240221 FALSE 0001706431 0001706431 2024-02-21 2024-02-21 0001706431 exch:XNAS 2024-02-21 2024-02-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 ________________________________________ Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) ________________________________________ Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1800 Owens Street , Suite 900 San Francisco , California 94158 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: ( 415 ) 906-4324 (Former Name or Former Address, if Changed Since Last Report) ________________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.0001 par value VIR Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, Vir Biotechnology, Inc. (the “Company”) and Glaxo Wellcome UK Limited (“GSK” and, together with the Company, the “Parties”) entered into a Definitive Collaboration Agreement on May 18, 2021 (the “DCA”). Under the terms of the DCA, the Parties agreed to collaborate on three separate programs, among them a program to research, develop and commercialize the Company’s monoclonal antibodies for the prevention, treatment or prophy

View on Read The Filing